Hera BioLabs develops proprietary preclinical research platforms, including the SRG Rat® model for human xenograft studies and the piggyBac® non-viral DNA delivery system for cell line engineering. These technologies provide researchers with reliable data and efficient models to accelerate drug discovery and development in oncology and other therapeutic areas.
Funding
$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery and development are often slowed by the lack of reliable preclinical models that accurately mimic human disease. Traditional animal models may not adequately represent human biology, leading to inaccurate data and increased development costs. Engineering custom cell lines and animal models with traditional methods can be time-consuming and inefficient.
Solution
Hera BioLabs offers preclinical research platforms and services designed to accelerate drug discovery and development. The company's SRG Rat® platform provides a highly immunodeficient rat model optimized for human xenograft studies, enabling more accurate oncology and pharmacology/toxicology research. Hera BioLabs also provides cell line engineering and custom research model development services using the piggyBac® non-viral DNA delivery system and Cas-CLOVER™ site-specific gene editing platform. These platforms and services provide researchers with customizable, efficient tools for generating reliable preclinical data.
Target Audience
Hera BioLabs serves researchers in oncology, metabolic diseases, infectious diseases, and bioprocessing, as well as pharmaceutical and biotechnology companies seeking to improve the predictability of their preclinical research.
Features
- SRG Rat®: A SCID rat with a double knockout of the Rag2 and Il2rγ genes, suitable for oncology, infectious disease, and pharmacology/toxicology studies.
- piggyBac® Non-viral DNA Delivery Platform: A system for cell line engineering and transgenesis, validated by over 750 peer-reviewed publications.
- Cas-CLOVER™ Site-Specific Gene Editing Platform: An alternative to CRISPR/Cas9 for building custom-designed nucleases and executing cell modifications.
- In vivo services: Comprehensive xenograft portfolio and in-house capabilities for efficacy and early safety evaluation.
- Cell line development: Services for producing proteins across research and biomanufacturing applications.
- Gene editing services: Commissioning of improved cell lines and animal models using gene editing technology.
- Gene editing reagents: Readily available reagents for in-house drug discovery programs.